Vanda Pharmaceuticals Inc. (VNDA)
Automate Your Wheel Strategy on VNDA
With Tiblio's Option Bot, you can configure your own wheel strategy including VNDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VNDA
- Rev/Share 3.4489
- Book/Share 8.2437
- PB 0.5574
- Debt/Equity 0.0239
- CurrentRatio 3.2507
- ROIC -0.1618
- MktCap 271514415.0
- FreeCF/Share -1.1172
- PFCF -4.1197
- PE -4.0497
- Debt/Assets 0.0186
- DivYield 0
- ROE -0.1289
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement
Published: August 29, 2025 by: Seeking Alpha
Sentiment: Positive
Vanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar I/schizophrenia (Feb 2026) and phase 3 data for MDD, plus tradipitant's motion sickness PDUFA (Dec 2025). Vanda's pipeline features a selective JAK2 inhibitor for polycythemia vera, recently granted Orphan Drug Designation, targeting a growing $2B market by 2032.
Read More
Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON, Aug. 21, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has asked Martin Makary, the Commissioner of the U.S. Food and Drug Administration (FDA) to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug Evaluation and Research (CDER), days before her retirement that upholds an Office of Generic Drugs decision to approve two generic versions of Hetlioz®. In 2023, Vanda filed citizen petitions challenging the FDA's approval of two generic versions of Vanda's drug Hetlioz®.
Read More
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability of HETLIOZ® (tasimelteon) to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no.
Read More
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.08 per share a year ago.
Read More
Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, Chairman and CEO Tim Williams - Senior Vice President and General Counsel Conference Call Participants Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Operator Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today.
Read More
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Read More
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). In 1886, Jean-Martin Charcot, Pierre Marie, and Henry Tooth independently described this hereditary motor and sensory neuropathy in their patients, paving the way for Charcot-Marie-Tooth (CMT) disease research.2,3 It was not …
Read More
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.
Read More
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023 Full year 2025 revenue expected to grow to $210 to $250 million Psychiatry portfolio revenue expected to grow to greater than $750 million in 2030 Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025 HETLIOZ® MAA for Smith-Magenis syndrome submitted in …
Read More
About Vanda Pharmaceuticals Inc. (VNDA)
- IPO Date 2006-04-12
- Website https://www.vandapharma.com
- Industry Biotechnology
- CEO Mihael H. Polymeropoulos
- Employees 368